International Journal of Clinical Pharmacy

, Volume 37, Issue 1, pp 105–112 | Cite as

Adverse drug reaction-related hospitalisations among patients with heart failure at two hospitals in the United Arab Emirates

  • Narjes Saheb Sharif-AskariEmail author
  • Syed Azhar Syed Sulaiman
  • Fatemeh Saheb Sharif-Askari
  • Ali Al Sayed Hussain
Research Article


Background Little is known about the adverse drug reaction (ADR) related admissions among heart failure (HF) patients. Objective The aim of this study was to determine the rate, factors, and medications associated with ADR-related hospitalisations among HF patients. Setting Two government hospitals in Dubai, United Arab Emirates. Methods This was a prospective, observational study. Consecutive adult HF patients who were admitted between December 2011 and November 2012 to the cardiology units were included in this study. The circumstances of their admission were analysed. Main outcome measures ADRs-related admissions of HF patients to cardiology units were identified and further assessed for their nature, causality, and preventability. Results Of 511 admissions, 34 were due to ADR-related hospitalisation (6.65, 95 % confidence interval 4.8–8.5 %). Number of medications taken by HF patients was the only predictors of ADR-related hospitalisations, where higher number of medications was associated with the odd ratio of 1.11 (95 % CI, 1.03–1.20, P = 0.005). More than one-third of ADR-related hospitalisations (35 %) were preventable The most frequent drugs causing ADR-related hospitalisation were diuretics (32 %), followed by non-steroidal anti-inflammatory drugs (15 %), thiazolidinediones (9 %), anticoagulants (9 %), antiplatelets (6 %), and aldosterone blockers (6 %). Conclusion ADR-related hospitalisations account for 6.7 % of admissions of HF patients to cardiac units, one-third of which are preventable. Number of medications taken by HF patients is the only predictors of ADR-related hospitalisations. Diuretic induced volume depletion, and sodium and water retention caused by thiazolidinediones and NSAIDs medications are the major causes of ADR-related hospitalisations of HF patients.


Adverse drug reaction Dubai Heart failure Hospitalisation United Arab Emirates 




Conflicts of interest


Supplementary material

11096_2014_46_MOESM1_ESM.docx (19 kb)
Supplementary material 1 (DOCX 18 kb)


  1. 1.
    Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15–9.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279(15):1200–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Wester K, Jönsson AK, Spigset O, Druid H, Hägg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol. 2008;65(4):573–9.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Einarson TR. Drug-related hospital admissions. Ann Pharmacother. 1993;27(7–8):832–40.PubMedGoogle Scholar
  5. 5.
    Catananti C, Liperoti R, Settanni S, Lattanzio F, Bernabei R, Fialova D, et al. Heart failure and adverse drug reactions among hospitalized older adults. Clin Pharmacol Ther. 2009;86(3):307–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Ogawa R, Stachnik JM, Echizen H. Clinical pharmacokinetics of drugs in patients with heart failure. Clin Pharmacokinet. 2013;52(3):169–85.PubMedCrossRefGoogle Scholar
  7. 7.
    Hillege HL, Girbes ARJ, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102(2):203–10.PubMedCrossRefGoogle Scholar
  8. 8.
    Hines PA, Yu K, Randall M. Preventing heart failure readmissions: is your organization prepared. Nurs Econ. 2010;28(2):74–86.PubMedGoogle Scholar
  9. 9.
    Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1991. p. 18–45.Google Scholar
  11. 11.
    Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little Brown; 1994. p. 253–6.Google Scholar
  12. 12.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRefGoogle Scholar
  13. 13.
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.PubMedCrossRefGoogle Scholar
  14. 14.
    Hallas J, Harvald B, Gram LF, Grodum E, BrØsen K, Haghfelt T, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med. 1990;228(2):83–90.PubMedCrossRefGoogle Scholar
  15. 15.
    Steyerberg EW, Eijkemans MJC, Harrell FE, Habbema JDF. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med. 2000;19(8):1059–79.PubMedCrossRefGoogle Scholar
  16. 16.
    Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Hallas J, Haghfelt T, Gram LF, Grodum E, Damsbo N. Drug related admissions to a cardiology department; frequency and avoidability. J Intern Med. 1990;228(4):379–84.PubMedCrossRefGoogle Scholar
  18. 18.
    Davidsen F, Haghfelt T, Gram LF, Brosen K. Adverse drug reactions and drug non-compliance as primary causes of admission to a cardiology department. Eur J Clin Pharmacol. 1988;34(1):83–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Onder G, Pedone C, Landi F, Cesari M, Della Vedova C, Bernabei R, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc. 2002;50(12):1962–8.PubMedCrossRefGoogle Scholar
  20. 20.
    van Der Hooft CS, Sturkenboom MCJM, van Grootheest K, Kingma HJ, Stricker BHC. Adverse drug reaction-related hospitalisations. Drug Saf. 2006;29(2):161–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Peyriere H, Cassan S, Floutard E, Riviere S, Blayac J-P, Hillaire-Buys D, et al. Adverse drug events associated with hospital admission. Ann Pharmacother. 2003;37(1):5–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Onder G, Petrovic M, Tangiisuran B, Meinardi MC, Markito-Notenboom WP, Somers A, et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score. Arch Intern Med. 2010;170(13):1142–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Sharif-Askari FS, Sulaiman SAS, Sharif-Askari NS, Hussain AAS. Development of an adverse drug reaction risk assessment score among hospitalized patients with chronic kidney disease. PLoS One. 2014;9(4):95991.CrossRefGoogle Scholar
  24. 24.
    Johnell K, Klarin I. The relationship between number of drugs and potential drug–drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish prescribed drug register. Drug Saf. 2007;30(10):911–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096–9.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Feenstra J, Grobbee DE, Mosterd A, Stricker BH. Adverse cardiovascular effects of NSAIDs in patients with congestive heart failure. Drug Saf. 1997;17(3):166–80.PubMedCrossRefGoogle Scholar
  27. 27.
    Marie H, Hugues R, Louise P. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ. 2005;330(7504):1370.CrossRefGoogle Scholar
  28. 28.
    Feenstra J, Heerdink ER, Grobbee DE, Stricker B. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the rotterdam study. Arch Intern Med. 2002;162(3):265–70.PubMedCrossRefGoogle Scholar
  29. 29.
    Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169(2):141–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Page J, Henry D. Consumption of nsaids and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160(6):777–84.PubMedCrossRefGoogle Scholar
  31. 31.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240–327.PubMedCrossRefGoogle Scholar
  32. 32.
    Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115(4):518–33.PubMedCrossRefGoogle Scholar
  33. 33.
    Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, et al. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005;11(8):861–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Yang T, Soodvilai S. Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res. 2008;2008:943614.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298(22):2634–43.PubMedCrossRefGoogle Scholar
  36. 36.
    Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes a retrospective cohort study. Diabetes Care. 2003;26(11):2983–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Dargie HJ, Hildebrandt PR, Riegger GAJ, McMurray JJV, McMorn SO, Roberts JN, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol. 2007;49(16):1696–704.PubMedCrossRefGoogle Scholar
  38. 38.
    Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129–36.PubMedCrossRefGoogle Scholar
  39. 39.
    Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–35.PubMedCrossRefGoogle Scholar
  40. 40.
    Komajda M, McMurray JJV, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31(7):824–31.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108(23):2941–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med. 2008;168(7):687.PubMedCrossRefGoogle Scholar
  43. 43.
    Raschke RA, Gollihare B, Wunderlich TA, Guidry JR, Leibowitz AI, Peirce JC, et al. A computer alert system to prevent injury from adverse drug events: development and evaluation in a community teaching hospital. JAMA. 1998;280(15):1317–20.PubMedCrossRefGoogle Scholar
  44. 44.
    Dormann H, Criegee-Rieck M, Neubert A, Egger T, Levy M, Hahn EG, et al. Implementation of a computer-assisted monitoring system for the detection of adverse drug reactions in gastroenterology. Aliment Pharmacol Ther. 2004;19(3):303–9.PubMedCrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  • Narjes Saheb Sharif-Askari
    • 1
    Email author
  • Syed Azhar Syed Sulaiman
    • 1
  • Fatemeh Saheb Sharif-Askari
    • 1
  • Ali Al Sayed Hussain
    • 2
  1. 1.Discipline of Clinical Pharmacy, School of Pharmaceutical ScienceUniversiti Sains MalaysiaPenangMalaysia
  2. 2.Pharmacy DepartmentDubai Health AuthorityDubaiUnited Arab Emirates

Personalised recommendations